摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methyl-4-oxo-2-phenyl-8-{3-[4-(2-trifluoromethanesulphonyloxyphenyl)-1-piperazinyl]-propylcarbamoyl}-4H-1-benzopyran | 335087-82-6

中文名称
——
中文别名
——
英文名称
3-methyl-4-oxo-2-phenyl-8-{3-[4-(2-trifluoromethanesulphonyloxyphenyl)-1-piperazinyl]-propylcarbamoyl}-4H-1-benzopyran
英文别名
8-{3-[4-(2-trifluoromethanesulphonyloxyphenyl)-1-piperazinyl]-propylcarbamoyl}-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran;[2-[4-[3-[(3-Methyl-4-oxo-2-phenylchromene-8-carbonyl)amino]propyl]piperazin-1-yl]phenyl] trifluoromethanesulfonate
3-methyl-4-oxo-2-phenyl-8-{3-[4-(2-trifluoromethanesulphonyloxyphenyl)-1-piperazinyl]-propylcarbamoyl}-4H-1-benzopyran化学式
CAS
335087-82-6
化学式
C31H30F3N3O6S
mdl
——
分子量
629.657
InChiKey
QDEMYUDOBJGGHG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    44
  • 可旋转键数:
    9
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    114
  • 氢给体数:
    1
  • 氢受体数:
    11

文献信息

  • BENZOPYRAN DERIVATIVES
    申请人:RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a.
    公开号:EP1222183B1
    公开(公告)日:2003-04-23
  • US6403594B1
    申请人:——
    公开号:US6403594B1
    公开(公告)日:2002-06-11
  • [EN] BENZOPYRAN DERIVATIVES<br/>[FR] DERIVES DE BENZOPYRANE
    申请人:RECORDATI CHEM PHARM
    公开号:WO2001029022A1
    公开(公告)日:2001-04-26
    Benzopyran derivatives (I) (R = phenyl, alkoxycarbonyl, alkylcarbonyl, CONH2, CONH(alkyl), CON(alkyl)2, CN or alkoxycarbonylamino; R2 = alkyl, alkoxy, polyfluoroalkoxy, OH or CF3SO2O; each of R4 and R5 independently = H, halogen, polyfluoroalkyl, polyfluoroalkoxy, CN or CONH2; n is 0, 1 or 2; but if R = Ph and both of R4 and R5 = H or hologen atoms, then R2 = polyfluoroalkoxy or CF3SO2O) and their N-oxides and pharmaceutically acceptable salts are endowed with adrenergic antagonist activity and, in particular, with high selectivity for the α1-adrenergic receptor as compared to the 5-HT1A receptor. This activity profile suggests the use of these benzopyran derivatives in the treatment of obstructive syndromes of the lower urinary tract, including BPH, without side-effects associated with hypotensive activity.
查看更多